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Abstract: Chromosomal instability (CIN) is an intricate phenomenon that is often found in human
cancer, characterized by persisting errors in chromosome segregation. This ongoing chromosome
mis-segregation results in structural and numerical chromosomal abnormalities that have been
widely described to promote tumor evolution. In addition to being a driver of tumor evolution,
recent evidence demonstrates CIN to be the central node of the crosstalk between a tumor and its
surrounding microenvironment, as mediated by the cGAS-STING pathway. The role that cGAS-STING
signaling exerts on CIN tumors is both complex and paradoxical. On one hand, the cGAS-STING
axis promotes the clearance of CIN tumors through recruitment of immune cells, thus suppressing
tumor progression. On the other hand, the cGAS-STING pathway has been described to be the
major regulator in the promotion of metastasis of CIN tumors. Here, we review this dual role of the
cGAS-STING pathway in the context of chromosomal instability and discuss the potential therapeutic
implications of cGAS-STING signaling for targeting CIN tumors.
Keywords: mitosis; cGAS; STING; chromosomal instability; aneuploidy
1. Chromosomal Instability (CIN) in Cancer
Chromosomal instability (CIN) is a process in which chromosome missegregation persists over
consecutive cell divisions [1]. CIN leads to genetic alterations, including chromosome copy number
changes that help cells to adapt when faced with stresses [2–4]. CIN should not to be mistaken
with aneuploidy. CIN is a condition as a result of which chromosome missegregation happens at
increased frequency, while aneuploidy is a state describing the actual abnormalities in chromosome
copy numbers. While CIN and aneuploidy often co-occur in tumors, [5] aneuploidy can also exist in the
absence of CIN, a condition known as stable aneuploidy [6]. An example of stable aneuploidy occurs,
for instance, in Down syndrome individuals whose cells all harbor one extra copy of chromosome 21.
Similarly, some cancers display high-grade aneuploidy without a CIN phenotype and are thus defined
to be stably aneuploid [6].
Many human tumors display a CIN phenotype, and the severity of the CIN phenotype correlates
with the stage of the affected tumors [7]. Yet, the relation between CIN and cancer is not as
straightforward as it seems. For instance, CIN is believed to drive cancer drug resistance [8,9]
through the generation of new karyotypes that include whole chromosome gains or losses (numerical
CIN) and structural changes to chromosomes (structural CIN) that help cancer cells to overcome the
drug-imposed cytotoxic effects [9]. However, elevating the CIN rates in tumors with pre-existing CIN
results in enhanced sensitivity to cytotoxic chemotherapies, such as cisplatin [10] and 5-fluorouracil
(5-FU) [11], which indicates that an excessive level of CIN is toxic for cancer cells.
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Whether CIN acts as an ally or a foe does not only depend on the CIN rates in the tumor, but also on
the interaction between the cancer cells and their microenvironment, including the immune component.
For instance, transcriptome analysis revealed that tumors with high aneuploidy show a reduced
infiltration of cytotoxic immune cells, in particular CD8+ T-cells [12] as compared to non-aneuploid
tumors. Another study analyzing more than 10,000 human cancers that were deposited at The Cancer
Genome Atlas (TCGA) showed a negative correlation between aneuploidy and leukocyte markers,
providing further evidence that CIN tumors need to duck the immune system [13]. The molecular
mechanism connecting a CIN phenotype to the immune system appears to be cyclic GMP AMP
synthase (cGAS), a cytosolic DNA sensor that activates the innate immune system. cGAS and its
downstream target STING are believed to form an essential node between cancer cells and the immune
microenvironment, as CIN often coincides with cytosolic DNA [14,15].
In this review, we will discuss recent findings that link CIN to the cGAS-STING axis and what is
known of the underlying molecular mechanism. We will highlight how pathway activation can affect
cancer cells’ viability, and under which conditions this is beneficial or detrimental for cancer cells in
relation to CIN. In addition, we will assess how these consequences could be exploited in therapy and
how this would influence the treatment window of cancer patients.
2. Upstream Triggers of the cGAS-STING Pathway
Discovered as a signaling cascade that detects viral DNA in the cytoplasm [16], more recently
cGAS-STING signaling has received a lot of interest from the CIN field. As the cGAS pathway is
activated through binding of cGAS to cytoplasmic double-stranded DNA (dsDNA) [16], it does not
only detect viral DNA, but also cytoplasmic dsDNA in micronuclei, an extra-nuclear body that contains
whole chromosomes or chromosome fragments that failed to be included in the main nucleus after
mitosis (Figure 1). Only when the membrane of the micronucleus ruptures, dsDNA becomes accessible
for cGAS binding [14,15] (Figure 1). Upon binding of dsDNA, cGAS undergoes a conformational change
that enables cGAS to produce cGAMP via its C-terminal domain by cyclizing ATP and GTP [16–18]
(Figure 1). While it has been reported that cGAS also binds to single stranded DNA (ssDNA) and
double stranded RNA (dsRNA) [19], this binding does not cause a conformational change in cGAS,
and therefore does not yield cGAMP production [20]. Additionally, cGAS seems to be activated by
dsDNA in a length dependent manner, as human recombinant cGAS is more efficiently activated
by larger DNA fragments (kilobase range) when compared to shorter fragments. The efficiency of
cGAS activation also dictates the downstream IFN production, with longer DNA fragments to be more
immunostimulatory [21].
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Figure 1. Cyclic GMP AMP synthase-STING (cGAS-STING) pathway signaling as activated by 
genomic instability. Cells with ongoing chromosomal instability (CIN) produce structures that 
contain genomic DNA, known as micronuclei. Upon the rupture of its membrane, dsDNA contained 
in a micronucleus is exposed to the cytoplasm and bound by cGAS. The binding of cGAS to dsDNA 
triggers the production of its secondary messenger, cGAMP that in turn binds and activates STING. 
Activated STING kinase translocates from the ER to the Golgi and phosphorylates its downstream 
targets, initiating (1) a TBK1-IRF3-type I interferon response, (2) a canonical NF-kB response, or (3) a 
non-canonical NF-kB response. * indicates stromal interaction molecule 1 (STIM1). 
Downstream of cGAS, cGAMP binds to STING (STimulator of INterferon Genes, Figure 1). 
Under unperturbed conditions, STING localizes to and is retained in the ER through its interaction 
with stromal interaction molecule 1 (STIM1, indicated as * in Figure 1) [22]. Upon the binding of 
cGAMP, STING undergoes a conformational change and translocates to the Golgi apparatus [23] 
(Figure 1). When localized to the Golgi, STING is palmitoylated at cysteine residues 88 and 91, which 
catalyzes the recruitment of TBK1 and its downstream component IRF3 [24]. STING-TBK1 binding 
leads to the phosphorylation of IRF3S386 and its dimerization, followed by IRF3 translocation into the 
nucleus to drive the transcription of interferon-β, mediating the type I IFN response and other IRF3 
target genes [25] (Figure 1). In addition, IRF3 nuclear translocation leads to STING degradation in 
endolysosomes to switch the signaling cascade back off [26]. Parallel to IRF 3 and type I IFNs 
activation, cGAS-STING pathway activation also leads to the activation of canonical and non-
canonical NF-kB (nuclear factor kB) in cancer cells, as further discussed below [27] (Figure 1). While 
both these pathways have strongly been implicated with regulation of cell death and immune 
activation, as discussed below, further work is required to better understand the interdependencies 
between these downstream branches. 
3. Downstream Effects of the cGAS-STING Pathway: The Innate Immune System Response 
3.1. Type I Interferon (IFN) Response and Signal Transducer and Activator of Transcription (STAT) 
Response 
The key output of the cGAS-STING signaling cascade is the upregulation of type I IFNs (Figure 
1). Type I IFNs are a family of monomeric cytokines consisting of 14 well-defined IFNα subtypes, 
Figure 1. Cyclic GMP AMP synthase-STING (cGAS-STING) pathway signaling as activated by genomic
instability. Cells with ongoing chromosomal instability (CIN) produce structures that contain genomic
DNA, known as micronuclei. Upon the rupture of its membrane, dsDNA contained in a micronucleus is
exposed to the cytoplasm and bound by cGAS. The binding of cGAS to dsDNA triggers the production
of its secondary messenger, cGAMP that in turn binds and activates STING. Activated STING kinase
translocates from the ER to the Golgi and phosphorylates its downstream targets, initiating (1) a
TBK1-IRF3-type I interferon response, (2) a canonical NF-kB response, or (3) a non-canonical NF-kB
response. * indicates stromal interaction molecule 1 (STIM1).
o nstrea of c S, c P binds to STI (STi ulator of I terferon enes, Figure 1).
nder unperturbed conditions, STI G localizes to and is retained in the ER through its interaction
ith stro al interaction olecule 1 (STI 1, indicated as * in Figure 1) [22]. pon the binding of
cG P, STI G undergoes a confor ational change and translocates to the Golgi apparatus [23]
(Figure 1). hen localized to the Golgi, STI G is pal itoylated at cysteine residues 88 and 91, hich
catalyzes the recruit ent of TBK1 and its do nstrea co ponent IRF3 [24]. STI G-TBK1 binding
leads to the phosphorylation of IRF3S386 and its dimerization, followed by IRF3 translocation into
the nucleus to drive the transcription of interferon-β, mediating the type I IFN response and other
IRF3 target genes [25] (Figure 1). In addition, IRF3 nuclear translocation leads to STING degradation
in endolysosomes to switch the signaling cascade back off [26]. Parallel to IRF 3 and type I IF s
activation, cGAS-STING pathway activation also leads to the activation of canonical and non-canonical
NF-kB (nuclear factor kB) in cancer cells, as further discussed below [27] (Figure 1). While both
these pathways have strongly been implicated with regulation of cell death and immune activation,
as discussed below, further work is required to better understand the interdependencies between these
downstream branches.
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3. Downstream Effects of the cGAS-STING Pathway: The Innate Immune System Response
3.1. Type I Interferon (IFN) Response and Signal Transducer and Activator of Transcription (STAT) Response
The key output of the cGAS-STING signaling cascade is the upregulation of type I IFNs (Figure 1).
Type I IFNs are a family of monomeric cytokines consisting of 14 well-defined IFNα subtypes, IFNβ,
and the more poorly understood cytokines IFNε, IFNκ, and IFNω [28]. Type I IFNs are known for two
major roles: (1) the regulation of the innate immune response and (2) the activation of the adaptive
immune system. In a cancer context, type I IFNs are mostly known for their cell-intrinsic tumor
suppressing role in premalignant cells through cell-intrinsic upregulation of p53, negative regulation
of cell proliferation, induction of apoptosis, and cell extrinsic activation of immune surveillance for
tumor cell clearance [29].
The canonical type I IFNs include IFN-α and IFN-β. The binding of IFN-α or IFN-β to their
respective receptors (IFNAR or IFNBR) leads to the activation of Janus kinase 1 (JAK1) and tyrosine
kinase 2 (TYK2), and downstream recruitment, dimerization, and nuclear translocation of STAT (Signal
Transducer and Activator of Transcription) proteins, as schematically shown in Figure 2 [29]. STAT
family member STAT1 binds to INF gamma-activated sequences (GASs) as a homodimer to promote
the transcription of pro-inflammatory genes, such as IRF1 and CXCL9 [30] (Figure 2). Conversely,
STAT3 homodimers are formed following the activation of JAK-JAK receptors, which in turn act as
suppressors of pro-inflammatory genes through an unknown transcriptional suppressor [31] (Figure 2).
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The cGAS-STING-driven type I IFN response activates the innate immune system and, in particular,
natural killer (NK) cells, which enhances their cytotoxic activity [32]. Impaired type I IFN signaling
thus impairs NK cells’ cytotoxic activity as the IFN signaling downstream cytokines, such as IL-15 and
IL-12, are required to prime NK cells towards their full competence [33]. Parallel to STAT1 activation,
cGAS-STING activity also promotes STAT3 activity, which counteracts STAT1-mediated activation
of NK cells in a negative feedback loop. As such, STAT3 promotes an immunosuppressive tumor
microenvironment, which can be partly attributed to reduced NK cell activity [34]. Furthermore,
STAT3 activation reduces tumor cell sensitivity for NK-mediated killing via alteration of NK-activating
ligands such as NKG2D [35]. Additionally, STAT3 activity decreases the migration of various immune
cells to the tumor microenvironment, including NK cells, T cells, neutrophils, and macrophages, further
contributing to an immunosuppressive tumor microenvironment [36]. Conversely, the inhibition of
STAT3 activity using STAT3 inhibitors elevates the level of chemoattractant chemokines, including
CCL2, CCL9, CCL12, and CCL17, and enhances tumor cell sensitivity to NK-mediated lysis [37].
Together, these features make STAT3 a promising therapeutic target.
3.2. Nuclear Factor kB (NF-KB) Response
The NF-kB family consists of five subunits: RelA, RelB, c-Rel, p50, and NF-kB p52, modulates the
immune response, cell survival, and proliferation [38], and can be activated by cGas signaling (Figure 1).
While the canonical NF-kB pathway primarily depends on a RelA/p50 dimer, non-canonical NF-kB
signaling relies on RelB and p52. Non-canonical NF-kB pathway activation is slow, being induced
by tumor necrosis factor receptor (TNFR) family members ligands, and persistent when activated.
The processing of p100 is a crucial step for non-canonical NF-kB pathway activation and is a tightly
regulated process. It results in the production of non-canonical NF-kB p52 and nuclear translocation of
NF-kB p52 and RelB, leading to transcriptional activation of a large number of genes and cytokines,
including CXCL1, CD44, and HIF-2α [39–41]
Aberrant non-canonical NF-kB activity has been associated with multiple malignancies, including
multiple myeloma, pancreatic cancer, prostate cancer, glioblastoma, and breast cancer [42]. For instance,
RelB expression in prostate cancer cells promotes epithelial-to-mesenchymal transition (EMT) and
negatively correlates with the survival of prostate cancer patients [43]. RelB expression is also increased
in ER negative breast cancer when compared to the less aggressive ER positive breast cancer [44].
In addition, RelB and its p52 binding partner are also known to regulate the activity of a group of
nucleic acid editing enzymes (APOBECs, [45]). The increased activity of APOBECs is believed to be
tumor promoting, as it induces mutations at cytosine residues with a thymine, for instance through
mutation, which increases RelB/p52 activity in breast and ovarian cancers [46].
4. The Bright Side: cGAS as a Suppressor of Chromosomal Instable Tumors
Chromosomal instability can, for instance, through the formation of micronuclei, lead to
cytoplasmic DNA and hence the activation of the cGAS-STING signaling axis [14,15,27]. The resulting
micronuclei can contain whole chromosomes as well as chromosome fragments, depending on the
type of CIN [47]. When micronuclei rupture, DNA becomes accessible for cGAS binding and thus
cGAS-STING pathway activation, ultimately driving the type I IFN response and immune surveillance,
as described above [14,15] (Figure 3A).
Cells 2019, 8, 1228 6 of 15
Cells 2019, 8, x 6 of 15 
 
 
Figure 3. The two faces of cGAS-STING signaling in cancer. (A) cGAS-STING acts as a tumor 
suppressor by initiating type I interferon signaling (STAT1 axis) and canonical NF-kB signaling. These 
signaling axes promote immune cell infiltration and cell death in tumors through modulation of 
transcription of pro-inflammatory and apoptosis signaling molecules. Conversely, it also triggers the 
other side of type I interferon signaling, the STAT3 axis, and the non-canonical NF-kB pathway to 
promote metastasis and tumor growth. (B) Other roles of cGAS-STING signaling: (1) a cell non-
autonomous role in which cancer cells’ DNA is engulfed by antigen presenting cells (APC) leading to 
activation of cGAS-STING signaling and cGAMP production in APCs. cGAMP is secreted by the 
APCs further stimulating immune infiltration (upper panel). (2) Nuclear cGas can also act as an 
inhibitor of homologous recombination-mediated DNA repair (lower panel). 
Cancer immune surveillance can be triggered through cell intrinsic and cell extrinsic cues. Cell 
intrinsic cGAS-STING activation typically results from chromosome segregation errors or DNA 
damage that lead to cytoplasmic DNA accumulation, including micronuclei. When micronuclei 
rupture, cGAS is activated followed by the downstream activation of type I IFN (Figure 3A). This will 
trigger the innate immune system as described above. Indeed, work from Santaguida et al. elegantly 
demonstrates that complex karyotypes induced in normally diploid retinal pigment epithelial (RPE1) 
upregulate the cGAS-STING pathway. The upregulation of the cGAS-STING pathway increases the 
expression of a number of cytokines, including IL-6 and CCL2 (Figure 3A). Indeed, RPE-1 cells with 
complex karyotypes are cleared by cultured natural killer cells (NK-92 cells) more efficiently in 
comparison to its wild type counterpart as a result of cGAS-STING pathway activation and the 
downstream type I IFN response [48]. 
cGAS-STING activity can also be triggered in a cell non-autonomous manner, for instance 
through uptake of cancer cells by antigen presenting cells (dendritic cells and macrophages [49], 
Figure 3B, upper panel). In this setting, DNA from the engulfed cells triggers the activation of the 
cGAS-STING signaling cascade. As shown for cell-intrinsic cGAS activation, cGAS cell-extrinsic 
activation also promotes the priming, expansion, and recruitment of tumor-specific T-cells through 
type I IFNs and their downstream pro-inflammatory molecules [50,51] (Figure 3A, B). In addition to 
that, cGAMP that is produced by cancer cells is secreted and taken up by dendritic cells, either 
through pinocytosis or endocytosis. This further boost STING and its downstream pathway 
activation in the dendritic cells through the production of IFNβ in a feed forward manner. 
In addition to modulating the innate immune system, cGAS also impinges on the adaptive 
immune system (Figure 3A). This followed, for instance, from observations that STING-deficient 
mice display decreased the infiltration of tumor-specific CD8+ cells and decreased levels of the T cell 
activation factors IL-12, CD86, and CD40 [52]. In this setting, cGAS-STING activates dendritic cells 
Figure 3. The two faces of cGAS-STING signaling in cancer. (A) cGAS-STING acts as a tumor suppressor
by initiating type I interferon signaling (STAT1 axis) and canonical NF-kB signaling. These signaling
axes promote immune cell infiltration and cell death in tumors through modulation of transcription of
pro-inflammatory and apoptosis signaling molecules. Conversely, it also triggers the other side of type
I interferon signaling, the STAT3 axis, and the non-canonical NF-kB pathway to promote metastasis
and tumor growth. (B) Other roles of cGAS-STING signaling: (1) a cell non-autonomous role in which
cancer cells’ DNA is engulfed by antigen presenting cells (APC) leading to activation of cGAS-STING
signaling and cGAMP production in APCs. cGAMP is secreted by the APCs further stimulating
immune infiltration (upper panel). (2) Nuclear cGas can also act as an inhibitor of homologous
recombination-mediated DNA repair (lower panel).
Cancer immune surveillance can be triggered through cell intrinsic and cell extrinsic cues.
Cell intrinsic cGAS-STING activatio typically sults from hromosome segregation errors or DNA
damage that lead to cytopl smic DNA accumulation, including micronuclei. Wh n micronuclei
ruptur , cGAS is activated followed by the downstream activatio of type I IFN (Figure 3A). This will
trigger the innate immune system as described above. Indeed, work from Santaguida et al. elegantly
demonstrates that co plex karyotypes induced in normally iploid retinal pigment epithelial (RPE1)
upregulate the cGAS-STING pathway. The upregulation of the cGAS-STING pathway increases
the xpression of a number of cytokines, including IL-6 and CCL2 (Figure 3A). Indeed, RPE-1 cells
with complex karyotypes are cleared by cultured n tural killer cells (NK-92 cells) more efficiently
in comparison to its wild type counterpart as a result of cGAS-STI G pathway activation and the
downstream type I IFN res onse [48].
cGAS-STING activity can also be triggered in a cell non-autonomous manner, for instance through
uptake of cancer cells by antigen pres ntin cells (dendritic cells and macrophages [49], Figure 3B,
upper panel). In this setting, DNA from the engulfed cells trigg rs the activation of the cGAS-STING
si naling cascade. As shown for cell-intrinsic cGAS activation, cGAS cell- xtrinsic activation also
promotes the priming, expansion, and recruitment of tumor-specific T-cells through type I IFNs and
their downstream pr -inflammatory molecules [50,51] (Figure 3A, B). In addition to that, cGAMP that
is roduced by cancer cells is secreted a d taken up by dendritic cells, either through pinocytosis or
endocytosis. T is further boost STING and its downstream pathway activation i the dendritic cells
t r the production of IFNβ in a feed forward manner.
In addition to modulating the innate imm ne system, cGAS also impinges o the adaptive
immune system (Figure 3A). This followed, for i stance, from observations that STING-deficient
ice display decreased the infiltration f tumor-specific CD8+ cells and decreased levels of the T cell
Cells 2019, 8, 1228 7 of 15
activation factors IL-12, CD86, and CD40 [52]. In this setting, cGAS-STING activates dendritic cells that
prime CD8+ T cells through cross-presentation. Furthermore, ectopic administration of cGAMP in vivo
has been shown to elevate the infiltration of tumor-specific CD4+ T-cells, macrophages, dendritic cells,
and CD8+ T-cells, leading to the increased production of type I IFN and ISGs. Finally, type I IFNs are
also responsible for the upregulation of Th1 chemokines, such as CXCL10 (Figure 3A), an important
chemokine for the homing of antigen-presenting cells and trafficking of CD8+ T-cells [53]. Together,
these observations strongly suggest that cGAS-STING signaling also has a role in modulating the
adaptive immune system.
Moreover, cGAS also acts as tumor suppressor independent to immune system signaling. For
instance, a non-canonical role of cGAS was recently reported as an instigator of mitotic cell death
during prolonged mitotic arrest [54] (Figure 3A). In this setting, cGAS activity triggers gradually
accumulating levels of phosphorylated IRF3 that promote mitotic cell death independent of type I
interferon induction, as evidenced by the lack of transcription of downstream type I IFNs proteins, such
as CXCL10, IFNB1, and IRF1. Instead, cGAS activity promoted the suppression of Bcl-xL dependent
inhibition of Mitochondrial Outer Membrane Permeabilization (MOMP), caspase activation and protein
substrate cleavage, which lead to mitotic cell death upon prolonged arrest.
Given that the cGAS-STING pathway plays an active role in eliminating tumor cells, one would
assume that the alleviation of the pathway would provide a powerful means for cancer cells to duck
immune surveillance, particularly when displaying a CIN phenotype. However, large scale cancer
sequencing datasets, such as The Cancer Genome Atlas (TCGA), reveal that genes encoding cGAS
or STING are rarely mutated when assessing more than 10,000 tumors. Only 0.6% of the tumors
have mutations in cGAS and 0.5% in STING with only half of these mutations leading to amino acid
changes [55]. Copy number loss of cGAS or STING is also rare, instead, amplifications are much more
common [56].
To further complicate matters, cGAS-STING levels in tumor cells vary greatly from one tumor
type to another. In colorectal cancer, the low expression of cGAS and STING is often associated
with more advanced stages of tumors. Similarly, the STING mRNA levels are reduced in progressed
gastric cancers. Yet, in breast, prostate, and head-and-neck tumors, cGAS and STING expression is
increased when compared to the healthy tissues [27,57–60]. The increased expression might result
from epigenetic deregulation, as breast, pancreatic, head-and-neck, and lung cancer frequently show
decreased methylation at cGAS and STING promotor regions. Therefore, apparently, despite the
predicted advantage of hiding from immune surveillance, the inactivation of the cGAS-STING signaling
axis is not a universal oncogenic path [55].
A part of the answer to this apparent paradox might be that the activation of the cGAS-STING
pathway in cancers does not always lead to downstream immune signaling. For example, the breast
cancer cell line MDA-MB-231 has a functional cGAS-STING axis, but pathway activation does not yield
a type I IFN response or any other immune signaling, which suggests that cancer cells have inactivated
the signaling route more downstream [27]. Several mechanisms might explain this:
A first possible mechanism that could explain active cGAS-STING without an immune response
is the inactivation of proteins more downstream in the pathway closer to the actual immune signaling.
For instance, the downstream effectors such as STAT1, JAK, and TYK2 are important triggers of the
type I IFN response. Indeed, the oncogenic tyrosine kinase NPM-ALK has been reported to bind
to and phosphorylate STAT1 [61], triggering its proteasome-dependent degradation. Additionally,
promoter methylation and thus reduced expression of STAT1 is common in head and neck cancer [62].
Furthermore, the activation of STAT1 negative regulators (i.e., SOCS (suppressor of cytokine signaling),
PTPs (protein tyrosine phosphatases), and PIAS (protein inhibitor of activated STAT)) is another route
that cancer cells take to block the type I IFN response. Indeed, STAT1 inhibitors SOCS1 and SHP1/2
(component of PTPs) are also commonly hyperactivated in breast cancer [63], and elevated expression
of PIAS1 has been observed in prostate and breast cancers [63–65]. Conversely, STAT3, the yang to
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STAT1′s yin, is a bona fide oncogene, which provides another route to counteract STAT1 activity. Indeed,
STAT1 and STAT3 ratios have long been recognized as a critical balance to regulate cell growth [66].
A second possible mechanism to silence cGAS-STING signaling downstream might relate to
p38-MAPK stress signaling. When the p38 MAPK-kinase stress response pathway is activated
alongside with cGAS, for instance, as a result of CIN, the cells fail to activate type I INFs [67]. A possible
mechanism for this negative interaction is that p38 MAPK signaling catalyzes phosphorylation of the
deubiquitinating enzyme USP21, which in turn inhibits STING activity [68]. This would thus prevent
type I INF activation without deregulating cGAS or STING expression levels, and thus be another
mechanism for cancer cells with a CIN phenotype to circumvent immune surveillance.
Whichever the underlying mechanism might be, one key conclusion is that tumors tend to block
IFN signaling preferentially downstream of cGAS and STING expression, which suggests that cGAS
and STING might have IFN-independent functions that are beneficial for cancer cells.
5. The Dark Side: cGAS-STING Signaling is Required for CIN Tumors
As discussed above, the frequent activation of cGAS and/or STING signaling in cancer strongly
suggests an oncogenic role for this pathway. One possible explanation comes from a recent study that
implicates cGAS and STING with a role in metastasis in CIN tumors ([27], (Figure 3A). This study
started from the observation that metastatic breast cancer clones often display more chromosomal
instability when compared to the primary tumor. For this, MDA-MB-231 breast cancer cells with or
without a CIN phenotype were transplanted into immunocompromised mice and metastatic events
were tracked while using a bioluminescence reporter to determine whether CIN would accelerate
metastasis. Mice that received MDA-MB-231 cells exhibiting a CIN phenotype displayed an average
survival of 70 days before succumbing to metastasis-related complications, while the mice transplanted
with MDA-MB-231 cells without a severe CIN phenotype survived much longer (up to 207 days) and
had lower metastatic burden when sacrificed. In addition to giving an increased metastatic burden,
MDA-MB-231 CINhigh cells had increased expression of EMT genes as compared to MDA-MB-231
CINlow cells. Further analysis revealed a strong correlation between inflammation-related genes,
CIN signature genes, and EMT genes, which suggests that the link between CIN and EMT might be
mediated through an inflammatory mechanism. Indeed, when metastasis latency and burden were
compared between MDA-MB-231 CINhigh cells with and without STING knockdown as a modulator
of the immune system, they found that functional STING was required for efficient metastasis. The
EMT phenotype and resulting metastasis critically relied on the activation of the non-canonical NF-kB
pathway (RelB/p52) as triggered by cGAS-STING signaling. Conversely, STING-depleted cells had
reduced nuclear RelB and downregulated expression of EMT genes, indicating that inactivating
components in non-canonical NF-kB signaling can prevent metastasis, an important clinical implication
that we will further discuss below.
In addition to promoting metastasis, cGAS has also been reported to promote tumorigenesis
by modulating the DNA damage response through the suppression of homologous recombination-
mediated DNA repair [69] (Figure 3B, lower panel). In their study, Liu et al. find that DNA damage
triggers Blk-mediated phosphorylation of cGasY215, leading to cGAS nuclear translocation. Nuclear
cGAS is recruited to the site of the double-stranded break, where it exerts a suppressive effect exclusively
on homologous recombination (HR)-mediated repair, while leaving the error prone non-homologous
end joining (NHEJ) pathway unaffected. The suppressive effect of cGAS on HR repair is mediated
through an interaction with PARP1 through PAR that prevents the formation of the PARP1-Timeless
complex. The observation that cGAS modulates HR is further supported by another study [70]
that demonstrates that cGAS inhibits homology-directed repair in a STING-independent manner.
Interestingly, the inhibition of ATM, a key player in the HR pathway, rescues the increase of DNA
breaks caused by cGAS, while the inhibition of DNA-PK, an effector in NHEJ, does not, providing
further proof for a role of cGAS in HR, but not in NHEJ. The proposed mechanism is that cGAS
interferes with Rad51-mediated DNA strand invasion by binding to the double strand template used
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by Rad51 filaments for repair, thus effectively inhibiting HR. These observations suggest that cGAS
can act as a suppressor of homology-directed repair, thus decreasing the efficiency of DNA repair thus
promoting tumorigenesis.
Together, these data reveal a darker side of cGAS-STING signaling, as a promotor of metastasis
and an inhibitor of homology-directed DNA repair, providing a possible explanation for the frequent
activation of cGAS-STING signaling in cancer.
6. Therapeutic Implications of Altered cGAS-STING Signaling
The dual role of cGAS in chromosomal instability as a tumor suppressor through its activation
of the innate immune system and, conversely, as a tumor promoter by inhibiting DNA repair and
promoting metastasis might come with important implications for cancer therapy.
Even though the cGAS-STING signaling axis has only recently been identified and many aspects of
this pathway need further investigation, many of the ‘classic’ chemotherapeutic and radiotherapeutic
approaches to eradicate cancer heavily rely on this signaling route (Figure 4A). For instance, etoposide
has previously been shown to induce the expression of inflammatory genes, such as IFNβ, IFNA4, and
IFI16 [71]. Similarly, dimethyloxoxanthenyl acetic acid (DMXAA), another chemotherapeutic agent,
induces IFNβ and primes CD8+ cells in a STING-dependent manner [72]. Cisplatin treatment has also
been reported to activate the cGAS-STING pathway, which boosts the expression of type I interferon
genes, such as CXCL9 and CXCL10 [73]. Both of the chemokines have been reported to recruit antigen
presenting cells and T cells to the tumors.
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Similar as described for chemotherapeutics, radiotherapy will trigger cGAS-STING signaling
through the generation of neo-epitopes that will activate dendritic cells, and through the accumulation
of cytoplasmic DNA that will directly trigger cGAS-STNG in the cancer cells (Figure 4A). The intimate
relationship between cGAS, DNA damage and the immune system opens up possibilities to exploit
radiotherapy-induced DNA damage to trigger the immune system to clear even more cancer cells [15].
Indeed, combining gamma radiation with immune checkpoint inhibitors appears to be a very powerful
cGAS-STING dependent approach for treating metastatic cancer in a mouse model for melanoma [15].
In addition to the more traditional anti-cancer therapies, more recently-developed targeted therapies,
such as DNA damage response (DDR) inhibitors (e.g., PARP inhibitors, Chk inhibitors, DNA-PK
inhibitors, ATR inhibitors), also activate cGAS-STING signaling and prompt the downstream immune
components entailed [74] (Figure 4A). Additionally, these compounds provoke cytosolic DNA fragments
that are recognized by cGAS following the activation of the pathway, emphasizing the strong synergy
between DNA damaging agents and cGAS-STING signaling in clearing cancer cells (Figure 4A).
As eluded to above, cGAS-STING dependent anti-tumor immunity is of crucial importance for
the success of immunotherapy, such as anti PD-1 and anti-PD-L1 immunotherapy (Figure 4A). This is
exemplified by a study showing that the PD-L1 inhibitors failed to give any anti-tumor effect in in
cGAS deficient mice [51]. Importantly, introducing cGAMP downstream of cGas rescued this effect,
providing strong evidence that cGAS-STING signaling is required for the therapeutic effect of immune
checkpoint inhibitors. Similarly, the STING agonist 2′3′-c-di-AM (PS) 2 (Rp, Rp) acts synergistically
with the immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 in clearing tumors [75]. Additionally,
in this setting, the STING agonist promoted tumor infiltration of cytotoxic T cells, which was fully
dependent on anti PD-1 or anti-PD-L1 treatment. These findings provide substantial proof for a
synergy between a chemotherapeutically-induced cGAS response and immune checkpoint blockade in
cancer therapy (Figure 4A).
Moreover, the recently-discovered non-canonical role of cGAS in promoting mitotic cell death
during a prolonged mitotic arrest [54] described above opens up yet another therapeutic implication.
Several commonly-used chemotherapeutic drugs (Vincristine, taxanes, etc.) act by prolonging mitosis
through interfering with the mitotic spindle dynamics (Figure 4A). Indeed, Paclitaxel shows increased
therapeutic efficiency in breast cancer cells that express high levels of cGAS. Therefore, high cGAS
expression might be a good predictor of clinical outcome when treating with microtubule poisoning
drugs, as cGAS expression would promote cell death in cells with prolonged mitotic arrest.
Our rapidly increasing understanding of the cGAS-STING signaling axis also leads to a better
understanding of which genetic contexts render cells more or less reliant on this pathway (Figure 4A, B).
For example, work from Heijink et al. shows that BRCA2 deficient breast cancer cells are more sensitive
to TNFα due to cGAS-STING activation [76]. BRCA2 deficient tumors have impaired homologous
repair, which leads to increased numbers of micronuclei, cGAS-STING activation, and a downstream
interferon response. The interferon response triggers activation of JNK and ASK1 kinases, tipping
the balance of TNFα-induced NF-kB pro-survival signaling towards pro-apoptotic signaling, thus
rendering these cells sensitive to TNAα. Similarly, ribonuclease H2 has been reported to induce
cGAS-STING signaling. Mice harboring a Rnaseh2bA174 mutation that show upregulation of interferon
stimulated genes (ISG) in various tissues as a result of cGAS-STING activation [14] are therefore also
expected to be very sensitive to TNFα, similar to BRCA2 deficient tumor cells. These observations
suggest that, while tumors that have cGAS-STING activation might have found ways to circumvent
the immune system, they can still be targeted by modulating the cGAS-STING pathway upstream to
trigger cell death.
However, activation of the cGAS-STING pathway does not always confer anti-tumor effects.
As discussed above, cGAS-STING signaling also facilitates metastasis in chromosomally instable cells.
Therefore, for cells exhibiting a CIN phenotype, the inhibition of cGAS or STING might a better
therapeutic option. Recently developed small molecule inhibitors for cGAS and STING can be used to
test this (Figure 4B). However, such compounds will also block innate immune surveillance [77,78] and,
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therefore, while such small molecule inhibitors have the potential to block CIN tumors from becoming
metastatic [27], cGAS/STING inhibition might come at the price of local immune suppression and thus
impaired tumor clearance. Therefore, further work is required to determine how this plays out in vivo.
Alternatively, as non-canonical NF-kB has been described to drive EMT and metastasis downstream of
cGAS-STING signaling, targeting essential components of this pathway is an option that be further
explored. However, more studies on the side effects of targeting this pathway are pivotal, given the
importance of NF-kB signaling.
From the work described above, an overall picture is emerging that the modulation of cGAS-STING
signaling can potentially be used to target cancer cells, but that the type of modulation (activating
or inactivating) is highly context dependent. While in genome-stable tumors ectopic induction of
the cGAS-STING pathway might be beneficial, as it would trigger type I IFNs and canonical NF-Kb
pathway promoting apoptosis, T-cells infiltration, and NK cells killing [56] (Figure 4A,B), cGAS-STING
signaling is constitutively activated in CIN tumors, and therefore the latter type of cancers have
presumably found ways to circumvent downstream immune surveillance. Therefore, the inhibition of
the cGAS-STING axis might be a better approach to target CIN tumors, as this would block the activation
of non-canonical NF-kB signaling, thus preventing an EMT phenotype and thus impairing metastasis.
While these clinical implications are still mostly hypothetical, together these findings strongly suggest
that the CIN status of a tumor could become a key determinant in treatment stratification.
7. Conclusions
Chromosomal instability has beneficial consequences for tumors, as it fuels tumors with the
potential to adapt their cells’ karyotypes, thus allowing for individual cancer cells to acquire new
features to adopt a more malignant fate [2,3]. Conversely, constant karyotype changes will also lead
to reduced cellular fitness for individual cells, which explains why cancer karyotypes recur between
tumors and are still reasonably constant when assessed at the population level, despite ongoing CIN
phenotypes [3]. The cGAS-STING signaling axis adds another layer of complexity to the role of
CIN in cancer. While the activation of cGAS-STING signaling in tumors might provide a powerful
means to mobilize immune surveillance and thus lead to tumor clearance, CIN tumors will likely have
adapted to sustained cGAS-STING signaling and thus have become insensitive. Intriguingly, CIN
tumors even seem to employ sustained cGAS-STING signaling to increase DNA damage and help
cells adopt a metastatic phenotype. Therefore, when combined with cytotoxic drugs, the inhibition of
cGAS-STING signaling could provide a powerful means for improving the outcome of CIN cancers.
However, more work is needed to further resolve the molecular players of this intriguing pathway and
to determine in which clinical settings activation or inhibition of this pathway can be employed in the
fight against cancer.
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